Drug profile · INN
biperiden hydrochloride
AKINETON
biperiden hydrochloride (AKINETON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — biperiden hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
biperiden hydrochloride (AKINETON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is biperiden hydrochloride?
biperiden hydrochloride (AKINETON) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for biperiden hydrochloride?
AKINETON is a marketed brand name for biperiden hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of biperiden hydrochloride?
biperiden hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.